Go to the list of all blogs
Anna G's Avatar
published in Blogs
Mar 24, 2021
TickeronGET DAILY SIGNALS
AstraZeneca (AZNCF, $99.60) vaccine linked to deadly blood clots in rare instances

AstraZeneca (AZNCF, $99.60) vaccine linked to deadly blood clots in rare instances

The coronavirus vaccine developed by AstraZeneca PLCΒ Β  has been linked to an autoimmune reaction that can lead to deadly blood clots in rare instances, according to a study by researchers in Norway and Germany.

According to the researchers in Norway and Germany, the vaccine could trigger an autoimmune reaction that causes blood to clot in the brain, the Wall Street Journal reported. The research could lead to a possible treatment to prevent the problem, the paper said. Symptoms such as dizziness and blurred vision occur several days after the vaccine is administered. But the condition can be detected by a simple blood test and easily treated in a hospital, according to the report.

Last week, there was a brief halting of the AstraZeneca vaccine rollout in Europe after several people who received the vaccine died. But later in the week, EU regulators allowed the use of the vaccine, after assessing that benefits far outweighed the risks of the vaccine.

Β 

Related Ticker: AZNCF
Related Portfolios: BIOTECHNOLOGY SECTOR
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Industry
N/A
Address
1 Francis Crick Avenue
Phone
+44 2037495000
Employees
89900
Web
https://www.astrazeneca.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
AstraZeneca (AZNCF, $99.60) vaccine linked to deadly blood clots in rare instances